Humacyte makes bioengineered human blood vessels, sold as Symvess, for hospitals and trauma centers. It last closed at $0.50 on Nov 17, down 7.27% on the day.
Only 1 firm rated HUMA in the past 90 days, not enough for a consensus
Average 12-month target
$0.60
▲ 19.8% upside
Based on 1 analyst who set a price target on HUMA in the past 90 days. The average target is $0.60, with a high of $0.60 and a low of $0.60, compared with the last close of $0.50.
Low $0.60Avg $0.60High $0.60
Blue marker: last close $0.50
Highest target$0.60
Average target$0.60
Lowest target$0.60
Latest rating changes
BarclaysTarget raised
Nov 11Hold$0.50 → $0.60
BarclaysInitiated
Oct 7Hold$0.50
TD CowenMaintained
Jun 17Buy$1.25
HC Wainwright & Co.Target raised
Jun 11Buy$3 → $4
BTIGReiterated
Jun 8Buy$2
Date
Firm
Action
Rating
Price target
Nov 11
Barclays
Target raised
Hold
$0.50 → $0.60
Oct 7
Barclays
Initiated
Hold
$0.50
Jun 17
TD Cowen
Maintained
Buy
$1.25
Jun 11
HC Wainwright & Co.
Target raised
Buy
$3 → $4
Jun 8
BTIG
Reiterated
Buy
$2
Loading…
Technical Analysis
HUMA · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock is 6% above its 20 day and 2% above its 50 day average. It is 55% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the 50 day average at $0.49, and the nearest resistance the swing high (Oct 29) at $0.51.
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 11.6%/day
Key levels
$1.5352 week high+206.0%
$0.77200 day average+54.0%
$0.58100 day average+16.0%
$0.55Pivot R1+10.0%
$0.53Pivot+6.0%
$0.51Swing high (Oct 29)+2.0%
$0.50Last close
$0.4950 day average−2.0%
$0.48Pivot S1−4.0%
$0.4720 day average−6.0%
$0.39Swing low (Oct 26)−22.0%
$0.3452 week low−32.0%
Indicators
RSI (14)
51.47
Middle of its range
Neutral
MACD
0.02
Above its signal line
Bullish
Stochastic
60.5
Middle of its range
Neutral
ADX (14)
22.7
Weak trend
Williams %R
-52.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
63.6
Oversold below −100, overbought above 100
Neutral
Rate of change
+13.7%
Change over 10 sessions
Bullish
ATR (14)
$0.06
Typical daily range, 11.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 27.8%/day
Key levels
$1.5352 week high+206.0%
$0.77200 day average+54.0%
$0.58100 day average+16.0%
$0.55Pivot R1+10.0%
$0.53Pivot+6.0%
$0.51Swing high (Oct 29)+2.0%
$0.50Last close
$0.4950 day average−2.0%
$0.48Pivot S1−4.0%
$0.4720 day average−6.0%
$0.39Swing low (Oct 26)−22.0%
$0.3452 week low−32.0%
Indicators
RSI (14)
41.31
Middle of its range
Neutral
MACD
-0.12
Above its signal line
Bullish
Stochastic
40.1
Middle of its range
Neutral
ADX (14)
17.5
No clear trend
Williams %R
-60.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-36.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−11.7%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 27.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HUMA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how HUMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow HUMA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How HUMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HUMA is in one of them and how their past HUMA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Humacyte
Humacyte is a biotechnology company based in Durham, North Carolina, that makes bioengineered human tissues for surgical repair and replacement. Its main product is an acellular tissue engineered vessel sold under the name Symvess, which is approved in the United States as a vascular conduit for adults with arterial injury to the limbs. The company is developing additional vessels for uses such as dialysis access and peripheral artery disease. Its vessels are shipped to hospitals, trauma centers and outpatient surgical settings.